CVS Health Corp CVS announced significant updates to its pharmacy benefits management division, CVS Caremark, which will reinstate coverage for Eli Lilly's weight-loss drug Zepbound and include the new oral medication Foundayo. This change is aimed at providing policyholders with a broader selection of GLP-1 medications and enhancing market competitiveness.
CVS Health's decision to reinstate Zepbound as a preferred medication on its formulary, effective October 1, 2026, is a strategic move following its removal in late 2024. The reinstatement comes as CVS Caremark aims to enhance its competitive edge against Novo Nordisk's Wegovy, which had previously taken precedence due to pricing considerations. Additionally, CVS Caremark will lift the new drug launch restriction on Foundayo starting June 1, 2026, allowing coverage for this newly approved oral weight-loss medication. CVS Caremark President Ed DeVaney emphasized that these changes stem from negotiations with pharmaceutical partners to improve drug affordability and accessibility, ultimately benefiting millions of Americans.
https://www.gurufocus.com/news/8888507/cvs-restores-coverage-for-eli-lillys-zepbound-cvs
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.